Changes in the Levels of Pro-Inflammatory Cytokines in Patients with Generalized Periodontitis and Hypertension, Depending on the Method of Treatment
PDF

Keywords

generalized periodontitis
tumor necrosis factor alpha
interleukin-6

How to Cite

Vicharenko, T., & Rozhko, M. (2017). Changes in the Levels of Pro-Inflammatory Cytokines in Patients with Generalized Periodontitis and Hypertension, Depending on the Method of Treatment. Galician Medical Journal, 24(4). https://doi.org/10.21802/gmj.2017.4.12

Abstract

Inflammatory mediators have an important role in the pathogenesis of periodontal disease. One of the leading mediators of the initiation of the pathological process is interleukin-1 (IL-1) – an endogenous pyrogen, a lymphocyte-activating factor. Numerous pro-inflammatory effects of interleukin-1β (IL-1β) occur in synergy with tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), effects on hematopoiesis, participates in nonspecific anti-infective defense.

The objective of the study is to determine levels of interleukin-6 and tumor necrosis factor alpha (TNF-α) in patients with hypertension II stage and generalized periodontitis of the II degree depending on the treatment method.

There were examined 30 patients with hypertension of the II stage and with generalized periodontitis of the II degree. Patients’ age ranged from 35 to 54 years. These patients were divided into two groups. The control group included 10 patients without general somatic pathology and with healthy periodontitis of the same age. 

The result of the analysis of tumor necrosis factor alpha (TNF-α) in patients in the first group before the treatment was 10.69±2.33 pg/ml. After the treatment this indicator was 6.97±1.57 pg/ml (p>0.1) in patients of the first group.

In patients of the second group the tumor necrosis factor alpha (TNF-α) was 9.49±2.2 pg/ml; after the treatment according to the offered scheme this figure decreased up to 2.77±0.9 pg/ml (p<0.01). The level of tumor necrosis factor alpha (TNF-α) in the control group was 1.5±0.77 pg/ml.

Interleukin-6 was 9.91±2.04 pg/ml before the treatment in the first group. After the treatment according to the standard scheme, the level of interleukin-6 was 6.33±0.97 pg/ml (p>0.1). In the second group, before the treatment the level of  interleukin-6 was 9.65±2.41 pg/ml; after the treatment according to the offered scheme it was 2.62±0.5 pg/ml (p<0.01). In the control group the interleukin-6 level was 2.24±0.51 pg/ml.

Analyzing the obtained results after the treatment in both groups we can conclude: after the treatment of generalized periodontitis of the II degree in patients with hypertension of the II stage, indices of pro-inflammatory cytokines decreased and ranged in normal limits; in patients from the second group (who received the offered scheme of treatment -including medicines) indexes of pro-inflammatory cytokines were significantly lower than in patients with the standard treatment scheme; the proposed scheme of treatment is more effective for treatment patients with generalized periodontitis of the II degree and hypertension of the II stage.

https://doi.org/10.21802/gmj.2017.4.12
PDF

References

Hao L, Li JL, Yue Y et al. Application of interleukin-1 genes and proteins to monitor the status of chronic periodontitis. Int. J. Biol. Markers. 2013;1:92-99. DOI: https://doi.org/10.5301/jbm.5000013 [PMid:23592003]

Chen Li-Li. Porphyromonas gingivalis lipopolysaccharide activated bone resorption of osteoblasts by inducing IL-1, TNF and PGE. Acta Pharmacol. Sin. 2001;7:614-618.

Delaleu N. Interleukin-1$beta and interleukin-18: regulation and activity in loca linflammation. Periodontology 2000. 2004;35:42-52. DOI: https://doi.org/10.1111/j.0906-6713.2004.003569.x [PMid:15107057]

Komatsu Y. Interleukin-6 (IL-6)-373 A9T11 allele is associated with reduced susceptibility to chronic periodontitis in Japanese subjects and decreased serum IL-6 level. Tissue Antigens. 2005;65:110-114. DOI: https://doi.org/10.1111/j.1399-0039.2005.00347.x [PMid:15663749]

Mashchenko IS. New aspects of the pathogenesis of generalized periodontitis. Visnyk stomatolohiyi. 2002;1:12-15.

Mashchenko IS. Exchange of cytokines in patients with generalized periodontitis. Sovremennaya stomatologiya. 2004;1:73-75.

Mashchenko IS. The cytokine status of patients with generalized periodontitis and its relationship to the state of bone metabolism. Ukrayinskyy stomatolohichnyy almanakh. 2005;2:5-8.

Melnychuk HM. Generalized periodontitis and periodontal disease: markers of hereditary predisposition, pathogenetic mechanisms of metabolic disorders and their complex correction: extended abstract of dissertation of a Degree of Candidate of Medical Scienses: Specialty 14.01.21 "Stomatolohiya". 2008;33.

Mykytenko AO. Pathogenetic substantiation of the effectiveness of multiprobiotic therapy in patients with chronic generalized periodontitis: extended abstract of dissertation of a Degree of Candidate of Medical Scienses: Specialty 14.03.04 "Patolohichna Fiziolohiya".2015;23-24.

Riznyk YB. Rationale for the correction of dysfunction of the endothelium of periodontal vessels in the complex treatment of patients with generalized periodontitis: extended abstract of dissertation of a Degree of Candidate of Medical Scienses: Specialty 14.01.22 "Stomatolohiya". 2016;29-33.

Toker H. Effect of periodontal treatment on IL-1beta, IL-1ra, and IL-10 levels in gingival crevicular fluid in patients with aggressive periodontitis. Clin. Periodontol. 2008;6:507-513. DOI: https://doi.org/10.1111/j.1600-051X.2008.01213.x [PMid:18371054]

Yucel-Lindberg T. Inflammatory mediators in the pathogenesis of periodontitis. Expert Rev. Mol. Med. 2013;5:15-17. DOI: https://doi.org/10.1017/erm.2013.8

Zaytseva EM. Clinico-microbiological parallels and cytokine profile in patients with periodontitis on a background of complex treatment using the liniment of cycloferon: extended abstract of dissertation of a Degree of Candidate of Medical Scienses: Specialty 14.00.21 "Stomatologiya". 2007; 24.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.